|
July 2002 (v02-n07) |
|
- Main Story - pgs. 1-16 Alteon Pharmaceuticals (AMEX:ALT)
- NIBM Model Portfolio Updates - pgs. 17-20
- Macro Market Commentary - pgs. 21-22
- Recommended Readings - pg. 23
- NIBM Model Portfolio - pg. 24
|
 |
|
| This month's Main Story is on Alteon
Pharmaceuticals. Based in New Jersey, this company concentrates on preventing or reversing
the aging process in human tissues - particularly the cardiovascular system. The company
has a number of orally-delivered, small-molecule drugs in development. Its lead drug had
nearly completed a rigorous Phase IIb program to treat isolated systolic hypertension. |
 |
|
| The following is an outline of this issue of
the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story - Alteon Pharmaceuticals
- Introduction/Summary
- Table: Basic Facts
- Investment Case
- Disclosures
Financing History
- Palladin/Promethean Toxic Convertibles
- Genentech Debentures
- Other recent financings
Sea change in treatment of coronary disease
- Changing ideas on hypertension
- Table: Blood pressure definitions
- Diastolic versus systolic
- Pulse pressure
- Big market
- Table: US population trend age 60
Reversing an irreversible component of aging
Alteon's pipeline
- ALT-711
- Phase IIa - systolic hypertension
- Table: ALT-711 Phase IIa results
- Phase IIb - SAPPHIRE and SILVER
- Phase IIa - DIAMOND for DHF
- Phase I - ESRD-PD
- Market
- Table: Action of common anti-hypertensives
- Table: Select branded anti-hypertensive drug sales
- Vanlev
- Pimagedine
- Bad, but not worthless
- Pimagedine partners
- Different approach
- ALT-4037
- ALT-946
- ALT-744
Operations
- Tarnished past
- Failed drug, lost partner
- Delisting
- Management shakeout
- Partnerships/Alliances
- Table: Alteon affiliations
Table: Alteon Milestones
What can go wrong?
- NIBM Model Portfolio and Updates
- PAREXEL
- Titan
- Dendreon
- Seattle Genetics
- Nabi Biopharmaceuticals
- Alliance Pharmaceutical
- Id Biomedical
- Genta
- Targeted Genetics
- AltaRex
- Macro Market Commentary
-
- Recommended Readings
|
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
